Model achieved balanced accuracy of 64.2 percent in internal validation, 63.7 percent in external validation.
News and Features
FDA approves novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.
Exxua is expected to be available in early 2024.
Increased risk for suicide seen among registered nurses, health technicians, health care support workers vs non-health care workers.
REL-1017 is an investigational oral, novel N-methyl-D-aspartate receptor channel blocker.
Likelihood of experiencing a serious medical outcome or being admitted to a health care facility was increased for children younger than 6 years.
Findings seen in real-world patients with a range of chronic health conditions.
Among patients with ADRD receiving care from a home health agency, antipsychotic use was tied to less improvement in activities of daily living.
Pitolisant is a selective histamine-3 receptor antagonist/inverse agonist.
Comparable rates of in-hospital adverse events seen among seniors prescribed oral antipsychotics after major surgery
Significant benefit seen as early as 8 days compared with placebo.
Selective serotonin reuptake inhibitor treatment tied to lower risk for maternal mental health problems and child externalizing behaviors across early childhood.
A 12-week app-based exercise program may reduce depressive symptoms in health care professionals, but adherence to the program may be an obstacle.
Recommendations include increase in research funding to screen and identify those at risk, connect with resources
Benzodiazepines, anxiety disorders linked to dementia risk, but no additional risk seen for benzodiazepines in patients with anxiety disorders.